Patent · US Active

Osteoclast inhibitors for bone marrow lesions

US9623038B2 · kind B2 · utility

59Cited by

46References

30Claims

0Family size

Assignee

ANTECIP BIOVENTURES II LLC · US

Inventors

Herriot Tabuteau · New York, US
Graeme Jones · Hobart, AU

Key dates

Filing date	Jul 22, 2016
Grant date	Apr 18, 2017
Priority date	—
Expiry date	Jul 22, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.